1,2,3,4-四氢异喹啉-3-甲酸甲酯盐酸盐 | 57060-88-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1,2,3,4-四氢异喹啉-3-甲酸甲酯盐酸盐
• 中文别名: 1,2,3,4-四氢-异喹啉-3-甲酸甲酯盐酸盐；(S)-1,2,3,4-四氢-3-异喹啉羧酸甲酯盐酸盐
• 英文名称: methyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate hydrochloride
• 英文别名: 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid,methyl ester hydrochloride；methyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate;hydrochloride
• CAS: 57060-88-5
• 化学式: C₁₁H₁₃NO₂*ClH
• mdl: MFCD00157120
• 分子量: 227.691
• InChiKey: BUXCBOUGBHWQBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.41
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  38.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 1,2,3,4-tetrahydro-isoquinoline-3-carboxylate, HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 1,2,3,4-tetrahydro-isoquinoline-3-carboxylate, HCl
CAS number: 57060-88-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H14ClNO2
Molecular weight: 227.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,2,3,4-四氢异喹啉-3-甲酸甲酯盐酸盐 在 aq. KOCN 作用下， 反应 12.0h， 以95%的产率得到(+/-)-10,10a-Dihydroimidazo<1,5-b>isoquinoline-1,3(2H,5H)-dione
  参考文献：
  名称：

  Jansa, Petr; Wsol, Vladimir; Bertolasi, Valerio, Heterocycles, 2006, vol. 68, # 12, p. 2527 - 2547

  摘要：

  DOI：
• 作为产物：
  描述：

  L-苯丙氨酸 在 盐酸 、 氯化亚砜 作用下， 以 水 为溶剂， 反应 8.0h， 生成 1,2,3,4-四氢异喹啉-3-甲酸甲酯盐酸盐
  参考文献：
  名称：

  Facile Preparation of optically Pure (3S)- and (3R)- 1, 2, 3, 4-Tetrahydroisoquinoline-3-carboxylic Acid

  摘要：

  光学纯的(3S)-1, 2, 3, 4-四氢异喹啉-3-羧酸(1)通过对其苄基酯(2b)的分馏结晶法轻松获得，该苄基酯是由部分消旋的1盐酸盐制备而成，随后经过催化去苄基化。同样，(3R)-1也是通过相同的程序制备的。在使用光学活性的苯丙氨酸进行Pictet-Spengler反应时，通过在存在手性位移试剂的情况下，对反应产物(1)所得到的相应甲基酯(2a)进行1H核磁共振(1H-NMR)光谱分析，确定了消旋化的程度。

  DOI：

  10.1248/cpb.31.312

文献信息

• [EN] SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS<br/>[FR] SULFONAMIDES SUBSTITUÉS UTILES COMME INHIBITEURS DE BCL ANTI-APOPTOTIQUES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012162365A1

  公开（公告）日：2012-11-29

  Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: W and Q and G are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bcl-2 family antiapoptotic proteins for the treatment of cancer; and pharmaceutical compositions comprising such compounds.

  揭示了式（I）的化合物或其药学上可接受的盐，其中：W、Q和G在此处被定义。还揭示了将这些化合物用作Bcl-2家族抗凋亡蛋白的抑制剂以治疗癌症的方法；以及包含这些化合物的药物组合物。
• An Old Story in the Parallel Synthesis World: An Approach to Hydantoin Libraries
  作者：Andrey V. Bogolubsky、Yurii S. Moroz、Olena Savych、Sergey Pipko、Angelika Konovets、Maxim O. Platonov、Oleksandr V. Vasylchenko、Vasyl V. Hurmach、Oleksandr O. Grygorenko

  DOI：10.1021/acscombsci.7b00163

  日期：2018.1.8

  An approach to the parallel synthesis of hydantoin libraries by reaction of in situ generated 2,2,2-trifluoroethylcarbamates and α-amino esters was developed. To demonstrate utility of the method, a library of 1158 hydantoins designed according to the lead-likeness criteria (MW 200–350, cLogP 1–3) was prepared. The success rate of the method was analyzed as a function of physicochemical parameters

  开发了一种通过原位生成的2,2,2-三氟乙基氨基甲酸酯与α-氨基酯反应平行合成乙内酰脲文库的方法。为了证明该方法的实用性，准备了根据铅样标准（MW 200–350，cLogP 1-3）设计的1158个乙内酰脲文库。分析了该方法的成功率与产品理化参数的关系，发现该方法可以被认为是用于铅导向合成的工具。通过合理设计，使用开发的方法进行平行合成，计算机模拟和体外筛选相结合的方法，发现了一种含乙内酰脲的超微摩尔主要分子，可作为Aurora激酶A抑制剂。
• N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
  申请人：——

  公开号：US20020193399A1

  公开（公告）日：2002-12-19

  Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

  化合物I的拮抗剂是VLA-4和/或alpha4/beta7，因此在抑制或预防细胞粘附和细胞粘附介导的病理过程中是有用的。这些化合物可以制成药物组合物，适用于治疗艾滋病相关痴呆、过敏性结膜炎、过敏性鼻炎、阿尔茨海默病、哮喘、动脉粥样硬化、自体骨髓移植、某些类型的毒性和免疫性肾炎、接触性皮肤过敏、炎症性肠病包括溃疡性结肠炎和克罗恩病、炎症性肺部疾病、病毒感染的炎症后遗症、脑膜炎、多发性硬化症、多发性骨髓瘤、心肌炎、器官移植、银屑病、肺纤维化、再狭窄、视网膜炎、类风湿性关节炎、脓毒性关节炎、中风、肿瘤转移、葡萄膜炎和I型糖尿病。
• [EN] ACYL ISOINDOLINE DERIVATIVES AND ACYL ISOQUINOLINE DERIVATIVES AS ANTI-VIRAL AGENTS<br/>[FR] DERIVES D'ACYLE ISOINDOLINE ET D'ACYLE ISOQUINOLINE UTILISES COMME AGENTS ANTIVIRAUX
  申请人：GLAXO GROUP LTD

  公开号：WO2004096774A1

  公开（公告）日：2004-11-11

  Anti-viral agents of Formula (I) wherein: R3 represents aryl or heteroaryl; R4 represents one or two substituents independently selected from hydrogen, C 1-6alkyl, halo, ORA , C(O)NRBRC, C(O)RD, CO2H, CO2RD, NRBRC, NRE C(O)RD, NRECO2RD, NREC(O)NRFRG, NRESO2RD, SO2NRFRG, SO2RD, nitro, cyano, heterocyclyl, heteroaryl, aryl, arylalkyl heteroarylalkyl or CF3; R5 and R6 independently represent hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; n represents 0 or 1; when n represents 0, R1 represents C(O)RH and R2 represents C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; when n represents 1, either i) R1 represents C(O)RH; R2 represents C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and R7 and R8 independently represent hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or ii) R1 and R2 independently represent hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; R7 represents C(O)RH; and R8 represents C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; RA represents hydrogen, C1-6alkyl, arylalkyl, heteroarylalkyl, aryl or heteroaryl; RB and RC independently represent hydrogen, C1-6alkyl, aryl or heteroaryl; or RB and RC together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; RD is selected from the group consisting of C1-6alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; RE represents hydrogen or C1-6alkyl; RF and RG are independently selected from the group consisting of hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; or RF and RG together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; RH represents hydroxy or NRBRC; and salts, solvates and esters thereof; provided that when RH is hydroxy, which is esterified to form -OR where R is selected from straight or branched chain alkyl, aralkyl, aryloxyalkyl, or aryl, then R is other than tert-butyl. Processes for their preparation and methods of using them in HCV treatment are provided.

  Formula（I）的抗病毒剂，其中：R3代表芳基或杂环芳基；R4代表一个或两个取代基，独立选择自氢、C1-6烷基、卤素、ORA、C（O）NRBRC、C（O）RD、CO2H、CO2RD、NRBRC、NREC（O）RD、NRECO2RD、NREC（O）NRFRG、NRESO2RD、SO2NRFRG、SO2RD、硝基、氰基、杂环烷基、杂环芳基、芳基、芳基烷基、杂环芳基烷基或CF3；R5和R6独立代表氢、C1-6烷基、芳基、杂环芳基、芳基烷基或杂环芳基烷基；n代表0或1；当n代表0时，R1代表C（O）RH，R2代表C1-6烷基、杂环烷基、芳基烷基或杂环芳基烷基；当n代表1时，要么i）R1代表C（O）RH；R2代表C1-6烷基、杂环烷基、芳基烷基或杂环芳基烷基；且R7和R8独立代表氢、C1-6烷基、芳基、杂环芳基、芳基烷基或杂环芳基烷基；或ii）R1和R2独立代表氢、C1-6烷基、芳基、杂环芳基、芳基烷基或杂环芳基烷基；R7代表C（O）RH；且R8代表C1-6烷基、杂环烷基、芳基烷基或杂环芳基烷基；RA代表氢、C1-6烷基、芳基烷基、杂环芳基烷基、芳基或杂环芳基；RB和RC独立代表氢、C1-6烷基、芳基或杂环芳基；或RB和RC与它们连接的氮原子一起形成5或6个成员饱和环；RD选自由C1-6烷基、芳基、杂环芳基、芳基烷基和杂环芳基烷基组成的群体；RE代表氢或C1-6烷基；RF和RG独立选择自氢、C1-6烷基、芳基、杂环芳基、芳基烷基和杂环芳基烷基组成的群体；或RF和RG与它们连接的氮原子一起形成5或6个成员饱和环；RH代表羟基或NRBRC；以及其盐、溶剂化合物和酯；但是当RH是羟基时，酯化形成-OR，其中R选择自直链或支链烷基、芳基烷基、芳氧基烷基或芳基，那么R不是叔丁基。提供了它们的制备方法以及在HCV治疗中使用它们的方法。
• (6a.alpha.,10a.alpha.,11a.alpha.)-2-(2-Pyridinyl)-1,3,4,6,6a,7,8,9,10,10
  申请人：Merck & Co., Inc.

  公开号：US04381302A1

  公开（公告）日：1983-04-26

  (6a.alpha.,10a.alpha.,11a.alpha.)-2-(2-pyridinyl)-1,3,4,6,6a,7,8,9,10,10a,1 1,11a-dodecahydro-2H-pyrazino[1,2-b]isoquinoline and derivatives or acid addition salts thereof are selective .alpha..sub.2 -adrenergic receptor antagonists and thereby useful as antidepressant agents and for treating sedation caused by antihypertensive therapy.

  (6a.alpha.,10a.alpha.,11a.alpha.)-2-(2-吡啶基)-1,3,4,6,6a,7,8,9,10,10a,11,11a-十二氢-2H-吡嗪[1,2-b]异喹啉及其衍生物或酸盐是选择性α2-肾上腺素能受体拮抗剂，因此可用作抗抑郁剂并用于治疗抗高血压治疗引起的镇静作用。